The safety of diabetes drug Avandia is again being questioned
-
Last Update: 2020-07-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
two U.Sdrugmanagement companies announcedsaturday thatwill remove the drug from thecatalog ofdrugs in both companiesthe safety of type 2 diabetes drug Avandiaearlier,found that Avandia could cause a higher risk of cardiovascular, and the U.SFood and Drug Administration subsequently evaluated the safety of the drug and asked manufacturers to add black-box warnings to their specificationsWhile the FDA does not believe that the data collected so far on theadverse reactions is not conclusive, the two major U.Sdrug management companies believe that they have decided to remove Avandia from its list of drugs based on overall consideration of patient interestsIn addition, U.Sscientists report in a new issue of The Journal of Nature Medicine that they have found in animal experiments that long-term use of the drug can lead to osteoporosis The researchers suggest that for patients who take Avandia for a long time, it is important to consider how to balance the side effects of osteoporosis, and for those with diabetes who are already at risk of osteoporosis, other diabetes medications should be taken Avandia, introduced in 1999, is an insulin hypersensitivity agent for the treatment of type 2 diabetes The drug, the best-selling drug owned by GlaxoSmithKline , Europe's largest pharmaceutical company, generated $3
.2
billion in global sales 2006 In the face of recent of questions about the safety of Avandia, glaxoSmithKline has long believed that Avandia is safe , and "more beneficial than bad" for patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.